First National Sleep Conference Explored Sleep's Role in
Public Health
Women's Health Initiative: Estrogen-Alone Study is Stopped,
Participants Begin Follow-up Phase
First National Sleep Conference Explored Sleep's Role in
Public Health
Evidence linking sleep with behavior, mood, and learning continues to accumulate.
Now, scientists are finding that reduced or disrupted sleep appears to increase
the risk of obesity, diabetes, and cardiovascular disease. The first national
sleep conference, "Frontiers of Knowledge in Sleep & Sleep Disorders
_ Opportunities for Improving Health and Quality of Life," was held March
29 and 30 on the NIH campus. It addressed the latest
evidence regarding sleep and sleep disorders, and explored ways to improve public
health and safety.
Sponsored
by the National Center on Sleep Disorders
Research (NCSDR), which is a component of the NHLBI, the conference was
attended by more than 400 health care providers, public health and education
experts, policy makers, patient advocates, and sleep medicine specialists. Conference
cosponsors were the American Academy of Sleep Medicine, the American Insomnia
Association, the American Sleep Apnea Association, the Narcolepsy Network, the
National Sleep Foundation, the NIH Office of Rare Diseases, the Restless Legs
Syndrome Foundation, and the Sleep Research Society.
The conference provided a forum for experts from a variety of fields to take
an interdisciplinary, systematic approach to bridging the gap between knowledge
and effective health care. Participants identified populations at risk and opportunities
for and barriers to improving public health. Their recommendations will be used
to formulate a national action plan for implementing clinical practice changes
and to expand the public's knowledge, attitudes, and behaviors related to sleep
to improve public health and quality of life.
The archived
videocast of the conference is available. Visit the NCSDR
Web site for more information on sleep and sleep disorders research.
Women's Health Initiative: Estrogen-Alone Study is Stopped,
Participants Begin Follow-up Phase
Participants in the estrogen-alone study of the Women's
Health Initiative (WHI), a large multi-center trial, have now begun the
follow-up phase of the study, after the NIH stopped the active component of
the trial.
After
considering the data, the NIH concluded that estrogen alone has no effect (either
increase or decrease) on heart disease, a key question of the study. However,
estrogen alone appears to increase the risk of stroke and decrease the risk
of hip fracture. No increased risk of breast cancer was observed during the
course of the study. (JAMA, 2004; 291:1701-1712.)
Another component of the WHI, a trial of estrogen plus progestin, also was
stopped early, in July 2002, because the risks were found to outweigh the benefits.
(JAMA, 2002; 288:321-333.)
The NIH is advising women to continue to follow the FDA
guidance regarding hormone therapy, which is that postmenopausal women who
use or are considering using estrogen or estrogen plus progestin should discuss
the risks and benefits with their physicians. The products are approved therapies
for relief from moderate to severe hot flashes and from symptoms of vulvar and
vaginal atrophy
Please send us your feedback, comments, and questions by using the appropriate link on the page, Contact the NHLBI.
Note to users of screen readers and other assistive technologies: please report your problems here.
PDF Version | Contents | Feature
Articles | In the News | Events and Meetings | Research and Resources
All Issues | FYI Index | NHLBI Express